Continuous adipose-derived stem cell therapy from the neonatal stage effectively reduces Duchenne muscular dystrophy symptoms in rats.
Kihara Y., Ikeda M., Takagi R., Ishigaki K., Yamanouchi K., Nagata S.
Animal Study, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cell Res Ther (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40859366
- PMCID
- PMC12382225
- DOI
- 10.1186/s13287-025-04594-x
Abstract (original English)
The optimal timing for mesenchymal stem cell (MSC) therapy in Duchenne muscular dystrophy (DMD) remains unclear. Neonatal DMD rats received intraperitoneal adipose-derived MSCs according to three schedules: early (postnatal days 1 and 14), continuous (days 1, 14, 28, and 42), or late (days 28 and 42). Wild-type rats and untreated DMD rats served as controls. Functional and histological outcomes were assessed on day 56. Continuous administration significantly attenuated the decline in grip strength across ten consecutive measurements (- 11% vs. -37% in DMD controls), and also reduced serum creatine kinase levels and diaphragmatic fibrosis (p < 0.05). Early or late treatment alone showed limited benefit. GFP-labelled cells were rarely detected in muscle, indicating minimal engraftment and suggesting paracrine-mediated effects. Molecular profiling showed lower CDKN2A together with higher CDKN1A, IL-10, VEGF-A and IGF-1 in the continuous group, revealing an anti-senescence, pro-regenerative profile that paralleled the functional gains. Early and sustained MSC administration offers superior structural and functional protection in DMD rats, highlighting the importance of treatment timing in maximizing therapeutic efficacy.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.